ST PHARM
IR Book

2025 3rd Quarter Earnings Call

ST PHARM

Cautionary Statement regarding Forward-looking Statement

This presentation contains forward-looking statements from Dong-A Socio Group ("the Group") that include, but are not limited to, statements regarding our future financial performance, business strategies, market opportunities, product development, and operational plans. Words such as "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "project," "will," and similar expressions are intended to identify such forward-looking statements.

These forward-looking statements are based on our current expectations and beliefs concerning future developments and their potential effects on the Group. Such forward-looking statements are inherently subject to risks, uncertainties, and assumptions that could cause actual results to differ materially from those expressed in these forward-looking statements.

We caution investors not to place undue reliance on any forward-looking statements. These statements speak only as of the date they are made, and we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. Additionally, please note that the financial figures and metrics presented in these Investor Relations materials are preliminary and have not yet been audited by an independent auditor. These numbers may be subject to change in future finalized disclosures.

2025 3rd Quarter Financial Results

Preliminary Consolidated Earnings



* "Etc." includes revenues from CRO subsidiaries, mRNA, etc.

Statement

'25.3Q Revenue ₩81.9 Billion, OP ₩14.7 Billion, NP ₩20.4 Billion

1) Diversification of revenue sources from Oligo CDMO a major development
2) Large contribution from Oligo CDMO business boosted topline revenue and margins
3) Expect positive growth trajectory throughout 4Q assuming current FX rate is maintained

[Unit: 1 Billion KRW]

Account Category	'25.3Q	'24.3Q	2024	YoY
Revenue	**81.9**	**61.7**	**273.8**	+32.7%
Cost of Goods Sold	44.9	39.2	177.6	+14.4%
Gros Profit	37.0	22.5	96.2	+64.6%
SG&A Expenses	22.3	16.4	68.5	+35.9%
R&D Expenses	6.7	5.6	22.1	+20.2%
Operating Profit	**14.7**	**6.1**	**27.7**	+141.6%
Net Profit	**20.4**	**13.7**	**32.5**	+49.2%
Gross Profit Margin	*45.2%*	*36.4%*	*35.1%*	*+8.8%p*
Operating Profit Margin	*18.0%*	*9.9%*	*10.1%*	*+8.1%p*
Net Profit Margin	*25.0%*	*22.2%*	*11.9%*	*+2.8%p*

2025 3rd Quarter Financial Results

ST PHARM

Revenue Breakdown

[Unit: 1 Billion KRW]

Segments		'24.3Q	'24.4Q	'25.1Q	'25.2Q	'25.3Q	YoY
Oligo	Total	35.6	81.2	37.6	43.5	68.6	+92.9%
	Comm.	29.6	55.5	32.4	37.2	34.1	+15.2%
	Clinical	5.9	26.8	5.1	6.3	34.5	+481.3%
Small Molecule		8.8	10.9	1.2	6.7	0.1	-99.1%
mRNA		0.8	0.4	0.6	0.7	1.4	+82.2%
Generic		12.0	15.2	5.3	8.9	2.4	-79.9%
Separate		**57.2**	**109.1**	**44.7**	**59.8**	**72.5**	**+26.9%**
Subsidiaries		4.5	6.7	7.7	8.4	9.3	106.9%
Consolidated		**61.7**	**115.7**	**52.4**	**68.3**	**81.9**	**32.7%**

Backlog Trend

[Unit: 1 Million USD]



* 25.09 Backlog may be subject to change depending on future currency exchange rates, shipment schedule, etc.

Comments

Oligo Revenue increased by 92.9% YoY
New Drug CDMO Projects increased to 43 projects from 30 (in '24)

Revenue Details

- Oligo API CDMO: ₩68.6 Billion (Commercial project portion = 49.6%)
  - New commercial projects' sales and clinical project recovery boosted sales
- Small Molecule: key project (Mitochondrial Deficiency) scheduled shipment in 4Q
- mRNA: ₩1.4 Billion revenue from early R&D stage projects (SmartCap©, etc.)
- CRO: ₩9.3 Billion revenue with profits at BEP level

Other Management/Business Comments

- Accumulated Total Backlog ≈ $243 Million (adjusted for 25.3Q Revenue)
  - Oligo Backlog ≈ $199 Million, Small Molecule Backlog ≈ $38.1 Million
- Newly added 9 Projects in Oligos, 4 Projects in Small Molecules (vs. end of 2024)

Upcoming

- [4Q] (SM) Mitochondrial Deficiency Project NDA approval

Thank You